1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Sanofi/Regeneron's Kevzara Priced To Break Into A Crowded Market

 
• By Jessica Merrill

The partners are looking to create a compelling value proposition for the interleukin-6 inhibitor, approved by FDA to treat moderate to severe RA, by pricing it below the market-leading anti-TNFs.

Sanofi and Regeneron Pharmaceuticals Inc. are looking to break into the crowded rheumatoid arthritis market by establishing a compelling value proposition for the interleukin-6 receptor blocker Kevzara (sarilumab). The wholesale acquisition cost of Kevzara is set at $39,000 per year for both the 200 mg and 150 mg doses, a price that is 30% lower than the two market-leading tumor necrosis factor inhibitors, AbbVie Inc.'s Humira (adalimumab) and Amgen Inc.'s Enbrel (etanercept).

Kevzara also could undercut Roche's entrenched IL-6 inhibitor Actemra (tocilizumab), depending on the dosing that is used, although not as substantially

More from Immunological

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

More from Therapy Areas